ABBV-400 in Select Advanced Solid Tumor Indications

Purpose of this Study

We are doing this study to find out if an experimental drug called ABBV-400 (the study drug) is a safe and effective option for treating various types of solid tumors.

Who Can Participate?

Eligibility

Adults ages 18+ who are diagnosed with one of the following types of cancer that is advanced or metastatic:<ul>
<li>Hepatocellular carcinoma (HCC); OR</li>
<li>Biliary tract cancer (BTC); OR</li>
<li>Pancreatic ductal adenocarcinoma (PDAC); OR</li>
<li>Esophageal squamous cell carcinoma (ESCC); OR</li>
<li>Triple-negative breast cancer (TNBC); OR</li>
<li>HR-positive and HER2-negative breast cancer (HR+/HER-); OR</li>
<li>Head and neck squamous cell carcinoma (HNSCC)</li></ul>
For more information about who can join this study, please contact the study team at gi-oncology-cru@dm.duke.edu or 919-668-1861.

What is Involved?

If you choose to join this study, you will:<ul>
<li>Get the study drug through an IV once every 3 weeks</li>
<li>Have a tumor biopsy done, if necessary</li>
<li>Have blood draws</li>
<li>Have imaging scans (CT or MRI)</li></ul>

Study Details

Full Title

A Phase 1 Open-Label Study to Evaluate the Efficacy and Safety of ABBV-400 in Select Advanced Solid Tumor Indications

Principal Investigator

John
Strickler

Protocol Number

PRO00113960

NCT ID

NCT06084481

Phase

I

Enrollment Status

Open to Enrollment